Expert Discusses Preventing Recurrence in HER2-Positive Breast Cancer
April 27th 2016In an interview with CURE, DeMichele explains the significance of the I-SPY 2 data, the advantages of Kadcyla versus standard of care and what is on the horizon for the use of Kadcyla in HER2-positive disease.
Read More
Immunotherapy the Foundation of Melanoma Care, Combinations on the Horizon
April 13th 2016An interview with Jason Luke, an assistant professor of Medicine at the University of Chicago Medicine, reveals that he thinks immunotherapy should become a main treatment for many patients with melanoma.
Read More